Using Antibody-Drug Conjugates for Treatment of AML
Alexander E. Perl, MD, discusses the use of antibody-drug conjugates in acute myeloid leukemia. Gemtuzumab ozogamicin has already been approved for this patient population.
Alexander E. Perl, MD, associate professor of medicine at the University of Pennsylvania, discusses the use of antibody-drug conjugates (ADC) in acute myeloid leukemia (AML). Gemtuzumab ozogamicin (Mylotarg) has already been approved for this patient population.
This agent was previously approved for relapsed disease, but withdrawn for single-agent use due to toxicity concerns.
Nonetheless, randomized data supported the use of this ADC in patients with AML. It is important to understand in which patients this treatment is most effective, which Perl notes as patients with relatively favorable chemotherapy-sensitive genotypes.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
